Additionally, in recent years, new migraine-specific medications, like CGRP-mAbs and gepants, have rapidly gained traction in Europe and the United States, which has undoubtedly reduced the adoption of memantine in migraine treatment. The gene discussed is CALCA; the disease is migraine disorder.